EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX‐FP in the PROLONG‐9FP clinical trial program

Hans-Juergen Laws, Katsuyuki Fukutake, Maria Fernanda Lopez-Fernandez, Yanyan Li, Wilfried Seifert, Annarita Tagliaferri

European Journal of Haematology · 2023

DOI: 10.1111/ejh.14010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Hans-Juergen Laws und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Paediatric Oncology, Haematology and Clinical Immunology, Centre for Child and Adolescent Health, University of Düsseldorf, Düsseldorf,…. Hauptthemen laut MEDLINE: Hemophilia B, Hemophilia A. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: CSL Behring.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To assess the impact of prophylaxis with rIX‐FP, a fusion protein linking recombinant factor IX (FIX) with human albumin, on joint outcomes.

Methods

Joint outcomes were assessed in pediatric (18 years) well‐controlled on a 14‐day regimen could switch to a 21‐day regimen. Target joints were defined as ≥3 spontaneous bleeds into a single joint within a 6‐month period.

Results

For adult/adolescent ( n = 63) and pediatric ( n = 27) patients, median (Q1, Q3) annualized joint bleeding rate was 0.39 (0.00, 2.31), 0.80 (0.00, 2.85), 0.20 (0.00, 2.58), and 0.00 (0.00, 1.78) when treated with 7‐, 10‐, 14‐, or 21‐day prophylaxis. 50.0%, 38.9%, 45.5%, and 63.6% of adult/adolescent patients had no joint bleeds when treated with 7‐, 10‐, 14‐, or 21‐day prophylaxis, respectively, and 40.7%, 37.5%, and 37.5% of pediatric patients had no joint bleeds when treated with 7‐, 10‐, or 14‐day prophylaxis. Ten adult and two pediatric patients developed target joints; all resolved by the end of the study.

Conclusion

Prophylaxis with rIX‐FP produced low joint bleeding rates and provided excellent hemostatic efficacy in the treatment of joint bleeds. All target joints reported resolved with rIX‐FP prophylaxis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia BHemophilia AAdultAdolescentHumansChildFactor IXRecombinant Fusion ProteinsHemostasisHemarthrosis

Stichwörter der Autor:innen

adulthemarthrosishemophilia Bjoint diseases

Substanzen

Factor IXRecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Paediatric Oncology, Haematology and Clinical Immunology, Centre for Child and Adolescent Health, University of Düsseldorf, Düsseldorf, Germany.
  • Department of Laboratory Medicine, Tokyo Medical University Hospital, Tokyo, Japan.
  • Department of Blood Coagulation, Ogikubo Hospital, Tokyo, Japan.
  • Haematology Department, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain.
  • CSL Behring, King of Prussia, Pennsylvania, USA.
  • Regional Reference Centre for Inherited Bleeding Disorders, University Hospital of Parma, Parma, Italy.

Förderung

  • CSL Behring

Zitieren

APA

Laws, H. J., Fukutake, K., Lopez-Fernandez, M. F., Li, Y., Seifert, W., & Tagliaferri, A. (2023). Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX‐FP in the PROLONG‐9FP clinical trial program. European Journal of Haematology. https://doi.org/10.1111/ejh.14010

Vancouver

Laws HJ, Fukutake K, Lopez-Fernandez MF, Li Y, Seifert W, Tagliaferri A. Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX‐FP in the PROLONG‐9FP clinical trial program. European Journal of Haematology. 2023. doi:10.1111/ejh.14010

BibTeX
@article{Laws2023,
  author = {Laws, Hans-Juergen and Fukutake, Katsuyuki and Lopez-Fernandez, Maria Fernanda and Li, Yanyan and Seifert, Wilfried and Tagliaferri, Annarita},
  title = {Assessment of joint bleeding and target joints in patients with severe or moderately severe hemophilia B (factor IX ≤2%) receiving prophylaxis with rIX‐FP in the PROLONG‐9FP clinical trial program},
  journal = {European Journal of Haematology},
  year = {2023},
  doi = {10.1111/ejh.14010}
}
Kostenlos starten →